Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults (Aged 18 Years and Older)

NCT07280858 is registered in ClinicalTrials.gov with SK Bioscience Co., Ltd. as lead sponsor.

NCT NCT07280858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07280858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults (Aged 18 Years and Older)
Lead sponsor
SK Bioscience Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 28, 2026
Completion date
September 12, 2028
Enrollment
368 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, sarbecovirus